Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 77.61

+3.5%

Nov 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1977)	1/15/2008 1:33:12 PM
From: Jibacoa	Read Replies (3) of 3722

ASTM was up 15.09% at its intraday H, but is up only 13% at present.<g> Volume is still < half its ADV. bigcharts.marketwatch.com It announced that the first patient has been treated with its autologous stem cell therapy for dilated cardiomyopathy. That is the first human application of Aastrom's CRC. CRCs are derived from a sample of patient's bone marrow that is processed using its Tissue Repair Cell technology to generate large numbers of stem and early progenitor cells. In February 2007, CRCs received an Orphan Drug Designation from the FDA for use in the treatment of DCM. ASTM also has development programs using TRC-based products for vascular, bone and neural tissue regeneration applications. The stock is trying to get off from the DT coming from its Oct4 H at $1.43 If it can get back above $1 it would be a good % gain.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next